SCHEMBL981295

SCHEMBL981295

NCc1ccc(C2(Cc3ccccc3)CCN(Cc3ccccc3)C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.50
OPRL1 P41146 2/20 0.46
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CCR3 P51677 1/20 0.45
POLB P06746 2/20 0.44
CYP3A4 P08684 2/20 0.44
HSD17B10 Q99714 1/20 0.44
OPRM1 P35372 1/20 0.43
SIGMAR1 Q99720 2/20 0.42
NPFFR1 Q9GZQ6 1/20 0.42
NPFFR2 Q9Y5X5 1/20 0.42
TSHR P16473 2/20 0.42
CYP2D6 P10635 1/20 0.42
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984578 0.87 NR3C1 (0.51) NR3C1OPRL1KMT2AKDM4ECCR3
SCHEMBL4712452 0.82 OPRL1 (0.54) OPRL1KMT2AKDM4ECCR3POLB
SCHEMBL981298 0.81 NR3C1 (0.48) NR3C1OPRL1KMT2AKDM4ECCR3
SCHEMBL27679284 0.77 OPRL1 (0.77) OPRL1KMT2AKDM4ECCR3POLB
SCHEMBL981130 0.76 OPRM1 (0.53) NR3C1KMT2AKDM4ECYP3A4HSD17B10
SCHEMBL2470240 0.76 MAOA (0.61) OPRL1KMT2ACCR3POLBCYP3A4
SCHEMBL984635 0.75 CYP2D6 (0.62) NR3C1OPRL1KMT2AKDM4ECCR3
SCHEMBL980880 0.74 SLC6A2 (0.61) NR3C1OPRL1KMT2AKDM4ECCR3
SCHEMBL984260 0.74 SLC6A2 (0.63) NR3C1KMT2AKDM4ESIGMAR1CYP2D6
SCHEMBL4506264 0.74 POLB (0.51) OPRL1KMT2AKDM4EPOLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 NR3C1 686/4885OPRL1 163/4885KMT2A 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.